Anzeige
Meldung des Tages: SGS liefert den Ritterschlag: Weltklasse-Tests machen aus einem Explorer plötzlich ein Industrie-Asset

Indivior Aktie News

Aktie
WKN:  A3DWFC ISIN:  GB00BN4HT335 US-Symbol:  INDV Branche:  Pharmazeutika Land:  USA
32,98 $
+0,03 $
+0,09%
28,208 € 21.01.26
Depot/Watchlist
Marktkapitalisierung *
3,83 Mrd. €
Streubesitz
16,91%
KGV
-
Dividende
0,42 €
Dividendenrendite
1,56%
Index-Zuordnung
-

Indivior News

02.06.25 - PR Newswire
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained PR Newswire
27.05.25 - PR Newswire
Indivior Announces Patrick Barry as Chief Commercial Officer
Indivior Announces Patrick Barry as Chief Commercial Officer PR Newswire
13.05.25 - PR Newswire
Indivior to Participate in Upcoming Investor Events
Indivior to Participate in Upcoming Investor Events PR Newswire
01.05.25 - PR Newswire
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy PR Newswire
24.04.25 - PR Newswire
Indivior Announces Q1 2025 Financial Results
Indivior Announces Q1 2025 Financial Results PR Newswire
04.03.25 - PR Newswire
Indivior Announces Further Changes to Board of Directors
Indivior Announces Further Changes to Board of Directors PR Newswire
27.02.25 - PR Newswire
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer PR Newswire
24.02.25 - PR Newswire
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-​release) Injection PR Newswire
20.02.25 - PR Newswire
Indivior Announces FY and Q4 2024 Financial Results
Indivior Announces FY and Q4 2024 Financial Results PR Newswire
12.02.25 - PR Newswire
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes PR Newswire

Newssuche

Videos

newspaper
20.01.26 +5,33%
Technical Trading: Gold Zukauf
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »